Innovent Biologics, Inc. (Innovent), a world-class biopharmaceutical company, and Eli Lilly and Company jointly announced a Distribution and Promotion Agreement in Mainland China regarding Lilly's non ...

Jaypirca®, the first and only non-covalent Bruton's tyrosine kinase (BTK) inhibitor approved by the U.S. FDA and China's National Medical (TASE:PMCN) Products Administration, is indicated for the ...

Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic ...

Jaypirca®, a highly selective kinase inhibitor, utilizes a novel non-covalent binding mechanism to re-establish BTK inhibition in mantle cell lymphoma (MCL) patients previously treated with a ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

Innovent will be responsible for the importation, marketing, distribution and promotion of Jaypirca ®; Lilly will be responsible for the R&D and post-market medical affairs of Jaypirca ®. Lilly is ...

SHANGHAI - Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of over $710 billion, have announced a new agreement ...